Straits Times Index
3,325.65 -0.63 (-0.02%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,089.93 +17.03 (+0.09%) FTSE 100
8,290.43 +42.64 (+0.52%) Bitcoin USD
61,491.03 +821.23 (+1.35%) CMC Crypto 200
1,275.77 -8.02 (-0.62%)
HALO Dec 2024 50.000 put
| Previous close | 3.9300 |
| Open | 3.9300 |
| Bid | 3.1000 |
| Ask | 3.5000 |
| Strike | 50.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.9300 - 3.9300 |
| Contract range | N/A |
| Volume | |
| Open interest | 112 |
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- PR Newswire
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
